Dehydro Nifedipine

CAS No. 67035-22-7

Dehydro Nifedipine( —— )

Catalog No. M34871 CAS No. 67035-22-7

Dehydro Nifedipine (BAY-b 4759) is the main metabolite of nifedipine in human plasma.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 38 In Stock
10MG 61 In Stock
25MG 123 In Stock
50MG 193 In Stock
100MG 310 In Stock
200MG 463 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Dehydro Nifedipine
  • Note
    Research use only, not for human use.
  • Brief Description
    Dehydro Nifedipine (BAY-b 4759) is the main metabolite of nifedipine in human plasma.
  • Description
    Dehydro Nifedipine (BAY-b 4759) is the main metabolite of nifedipine in human plasma. Dehydro Nifedipine inhibits glucose uptake in PC-12 cells with an IC50 value of 130 μM. Nifedipine is a calcium channel blocker used in the treatment of hypertension and angina. Dehydronifedipine is formed when it is metabolized by cytochrome P450 (CYP) isomers CYP3A4 and CYP3A5.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Drug Metabolite
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    67035-22-7
  • Formula Weight
    344.32
  • Molecular Formula
    C17H16N2O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    COC(=O)c1c(C)nc(C)c(C(=O)OC)c1-c1ccccc1[N+]([O-])=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Ethacridine lactate

    Ethacridine lactate is a poly(ADP-ribose) glycohydrolase (PARG) inhibitor.

  • Kisspeptin-54 (27-54...

    Kisspeptin-54 (27-54) (human) is a polypeptide that can be used for compound synthesis and pharmaceutical research.

  • TP0586532

    TP0586532 is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk.